Risk of venous thromboembolism with bevacizumab in cancer patients.
Saadettin
S
Kilickap
Cagatay
C
Arslan
D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D000068258:Bevacizumab; D002405:Catheterization, Central Venous; D005472:Fluorouracil / Q000009:adverse effects; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D012306:Risk; D054556:Venous Thromboembolism / Q000209:etiology*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab; D005472:Fluorouracil